WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
Extreme Risk
This substance is in the extreme platform risk category due to growth-factor signaling, mitogenic potential, or complete absence of human safety data. Exercise maximum caution.
Mitogenic Risk
This substance has mitogenic (cell-proliferation-promoting) properties. Growth-factor class risks include hypoglycemia and potential promotion of abnormal cell growth.
Evidence visual
IGF-1 LR3 evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
extreme
Regulatory
not approved
WADA
S2
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
IGF-1 LR3 (Long R3 IGF-1) is an engineered IGF-1 analogue with reduced binding to IGF binding proteins and prolonged activity versus native IGF-1. Animal research shows superior potency to injected IGF-1. Growth-factor class risks include hypoglycemia and mitogenic signaling. WADA lists IGF-1 and analogues under S2. This is an extreme compliance risk item for any consumer-facing platform.
Decision path
Where IGF-1 LR3 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether IGF-1 LR3 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
IGF-1 receptor agonism with altered binding protein interactions; prolonged activity vs native IGF-1.
subcutaneous
Animal research: injection/infusion comparisons. No established human consumer dosing.
Growth factor signaling; muscle growth narratives in gray market. High mitogenic/glucose risk.
Acute metabolic effects possible; anabolic narratives are speculative in consumer context.
Active malignancy (by analogy to growth factor class). High interaction potential with insulin/glucose-lowering agents.
Hypoglycemia, mitogenic signaling, growth-factor class risks.
High interaction potential with insulin/glucose-lowering agents; avoid prescriptive guidance.
Cost at a glance
Typical cycle cost
$97.99
Estimated monthly
$130.65
Protocol style
2-4 week burst
Short burst
Estimate confidence
High confidence
Assumes roughly 0.6 mg–1.4 mg per cycle, using 1 tracked affiliated listing.
Modeled as a short experimental run because there is no formal human cycle guidance.
Known Interactions
Tesamorelin increases IGF-1 (label); combining with IGF-axis agonists increases proliferative/hypoglycemia monitoring complexity.
High-risk IGF/MGF clustering; insufficient safety basis for consumer routing; FDA flags PEG-MGF compounding risks and no identified human exposure data.
Growth-factor cluster; strong clinical-only gating recommended.
FOXO4-DRI is a senolytic research peptide with limited human data; avoid combining with high-mitogenic axis in consumer protocols.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for IGF-1 LR3.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.